Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities

The heterogeneity of IDH1/2 wild-type glioblastoma limits its prognosis and therapy. Here, the authors show a binary stratification, based on quantitative proteomic analysis of samples from patients with glioblastoma, with different prognosis and therapeutic vulnerabilities.

Saved in:
Bibliographic Details
Main Authors: Sejin Oh, Jeonghun Yeom, Hee Jin Cho, Ju-Hwa Kim, Seon-Jin Yoon, Hakhyun Kim, Jason K. Sa, Shinyeong Ju, Hwanho Lee, Myung Joon Oh, Wonyeop Lee, Yumi Kwon, Honglan Li, Seunghyuk Choi, Jang Hee Han, Jong Hee Chang, Eunsuk Choi, Jayeon Kim, Nam-Gu Her, Se Hoon Kim, Seok-Gu Kang, Eunok Paek, Do-Hyun Nam, Cheolju Lee, Hyun Seok Kim
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
Science
Q
Online Access:https://doaj.org/article/4661a5f377d24eba844773750fa5ffeb
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/4661a5f377d24eba844773750fa5ffeb

Similar Items